Immunogen (IMGN) surges on 'home run' ovarian cancer treatment trial data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq leads Wall St higher as Nvidia eases AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil prices rise as investors weigh lack of progress in Middle East negotiations
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Immunogen Inc. (IMGN) Elahere Data 'Simply Mirvelous!' - BMO
May 3, 2023 7:39 AM EDTBMO Capital analyst Etzer Darout reiterated an Outperform rating and $19.00 price target on Immunogen Inc. (NASDAQ: IMGN) following positive phase 3 data on ELAHERE. The analyst called the results "simply mirvelous!'
The analyst commented, "This morning IMGN announced that the Phase 3 MIRASOL trial studying... More
Immunogen Inc. (IMGN) PT Raised to $15 at Truist Securities on 'Home Run' Data
May 3, 2023 7:35 AM EDTTruist Securities analyst Asthika Goonewarden raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $15.00 (from $11.00) while maintaining a Buy rating, calling today's data a "home run."
The analyst commented, "We view the topline data reported this morning as a home run. MIRASOL not... More
Immunogen (IMGN) Climbs 89% After Study Shows OS Benefit in Phase 3 MIRASOL Trial in Patients with FRĪ±-Positive Platinum-Resistant Ovarian Cancer
May 3, 2023 7:09 AM EDTImmunogen (NASDAQ: IMGN) Climbs 89% After Study Shows OS Benefit in Phase 3 MIRASOL Trial in Patients with FR-Positive Platinum-Resistant Ovarian Cancer
Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to ChemotherapyFirst Medicine to Demonstrate an Overall Survival Advantage in... MoreImmunogen (IMGN) Reports ELAHERE Demonstrated Overall Survival Benefit in Phase 3 Trial
May 3, 2023 6:41 AM EDTImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FR)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. Based on these data, the Company plans to submit a Marketing Authorization Application (MAA) in Europe and a supplemental Biologics License Application (sBLA) in the US for... More
Immunogen Inc. (IMGN) PT Raised to $11 at Truist Securities
May 2, 2023 9:14 AM EDTTruist Securities analyst Asthika Goonewarden raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $11.00 (from $10.00) while maintaining a Buy rating.... More
